Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) - Research analysts at Leerink Partnrs reduced their Q3 2025 earnings per share (EPS) estimates for Design Therapeutics in a report released on Tuesday, August 12th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will earn ($0.35) per share for the quarter, down from their previous estimate of ($0.33). The consensus estimate for Design Therapeutics' current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Design Therapeutics' Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.35) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.45) EPS and FY2027 earnings at ($1.70) EPS.
Design Therapeutics Stock Performance
Shares of Design Therapeutics stock traded down $0.23 on Friday, reaching $5.17. 218,746 shares of the stock were exchanged, compared to its average volume of 133,939. The firm's 50 day moving average is $4.07 and its 200-day moving average is $4.08. The firm has a market cap of $294.43 million, a PE ratio of -4.62 and a beta of 1.58. Design Therapeutics has a one year low of $2.60 and a one year high of $7.77.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.02).
Institutional Trading of Design Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the stock. ProShare Advisors LLC bought a new stake in Design Therapeutics during the fourth quarter valued at $71,000. Invesco Ltd. acquired a new stake in shares of Design Therapeutics in the 4th quarter worth about $71,000. Los Angeles Capital Management LLC bought a new position in shares of Design Therapeutics during the 2nd quarter worth approximately $43,000. Velan Capital Investment Management LP bought a new position in shares of Design Therapeutics during the 1st quarter worth approximately $54,000. Finally, Jane Street Group LLC bought a new position in shares of Design Therapeutics during the 1st quarter valued at approximately $70,000. Institutional investors and hedge funds own 56.64% of the company's stock.
Design Therapeutics Company Profile
(
Get Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Recommended Stories
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access